Eurofarma Laboratorios S.A.
eurofarma.com.brLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
63
Active
8
Phase 3
53
Total enrollment
13,592
Pipeline matrix
Showing 11 of 11 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Experimental drug | — | — | — | — | — | 2 | |
| N0783 | — | — | — | — | — | 1 | |
| Alenia® | — | — | — | — | — | 1 | |
| N0728 | — | — | — | — | — | 1 | |
| Vesomni® | — | — | — | — | — | 1 | |
| Minoxidil oral solution | — | — | — | — | — | 1 | |
| Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg | — | — | — | — | — | 1 | |
| Comparator - Trimbow® | — | — | — | — | — | 1 | |
| N0877 | — | — | — | — | — | 1 | |
| Benicar HCT ® Tablets 40 mg/25 mg | — | — | — | — | — | 1 | |
| N1087 | — | — | — | — | — | 1 |
Next readouts
- 2027-02
- 2028-03
- 2028-04-30
- 2028-04-30
- 2028-07
- 2028-08
- 2028-10-30
Top conditions
- Skin Care4
- Allergic Rhinitis3
- Asthma3
- Moderate Asthma2
- Diabetes Mellitus, Type 22
- Gastroesophageal Reflux Disease2
- Pain2
- Overweight2
Frequently asked questions about Eurofarma Laboratorios S.A.
- How many clinical trials does Eurofarma Laboratorios S.A. have on ClinicalTrials.gov?
- Eurofarma Laboratorios S.A. is listed as the lead sponsor on 63 clinical trials in ClinicalTrials.gov, 8 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Eurofarma Laboratorios S.A.'s trials are in Phase 3?
- 53 of Eurofarma Laboratorios S.A.'s trials are in Phase 3, spread across 11 active drug programs.
- What therapeutic areas does Eurofarma Laboratorios S.A. focus on?
- Eurofarma Laboratorios S.A.'s most-studied conditions on ClinicalTrials.gov are Skin Care, Allergic Rhinitis, Asthma, Moderate Asthma, Diabetes Mellitus, Type 2.
- When are Eurofarma Laboratorios S.A.'s next clinical trial readouts?
- Eurofarma Laboratorios S.A. has 7 upcoming primary-completion readouts tracked here; the soonest is “Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris”, expected around 2027-02.